Immunotherapy has emerged as a pivotal field in cancer treatment, particularly for lymphomas, which include both Hodgkin and non-Hodgkin variants. Rituximab, a pioneering cancer immunotherapy, remains integral to the treatment regimens for B cell non-Hodgkin lymphomas. Recent advancements have seen the approval of CD19-directed chimeric antigen receptor (CAR) T cell therapies and CD20 x CD3 bispecific antibodies for relapsed and refractory aggressive B cell non-Hodgkin lymphomas. Additionally, immune checkpoint inhibitors and CD30 antibody-drug conjugates have significantly improved treatment outcomes for classical Hodgkin lymphoma. Despite these advancements, the clinical results remain suboptimal, highlighting the need for further enhancement of therapeutic options. Current research is focused on addressing these gaps by exploring novel strategies to bolster both innate and adaptive immune responses against cancer, thereby improving the efficacy of immunotherapy for lymphomas.
This research topic aims to explore and develop novel strategies to enhance clinical immunotherapy for both Hodgkin and non-Hodgkin lymphomas. The primary objective is to identify and investigate innovative approaches that can improve the effectiveness of current treatments. This includes examining new methods to augment innate and adaptive immune responses, as well as evaluating relevant preclinical and clinical studies that could lead to better therapeutic outcomes for patients with lymphoid neoplasms.
To gather further insights into the field of lymphoma immunotherapy, we welcome articles addressing, but not limited to, the following themes:
- Tumor microenvironment in Hodgkin and non-Hodgkin lymphomas
- Immune defects in Hodgkin and non-Hodgkin lymphomas
- Studies of innate and adaptive immune responses relevant to immunotherapy for lymphoma
- Use of cellular therapies in Hodgkin and non-Hodgkin lymphomas
- Novel approaches to autologous or allogeneic stem cell transplantation
- Novel combinations with immune checkpoint inhibitors
- Novel combinations with monoclonal antibodies and bispecific antibodies
- Use of antibody-drug conjugates in the treatment of Hodgkin and non-Hodgkin lymphomas
- Cytokine-based immunotherapy for lymphoma
- Vaccine-based immunotherapy for lymphoma
Immunotherapy has emerged as a pivotal field in cancer treatment, particularly for lymphomas, which include both Hodgkin and non-Hodgkin variants. Rituximab, a pioneering cancer immunotherapy, remains integral to the treatment regimens for B cell non-Hodgkin lymphomas. Recent advancements have seen the approval of CD19-directed chimeric antigen receptor (CAR) T cell therapies and CD20 x CD3 bispecific antibodies for relapsed and refractory aggressive B cell non-Hodgkin lymphomas. Additionally, immune checkpoint inhibitors and CD30 antibody-drug conjugates have significantly improved treatment outcomes for classical Hodgkin lymphoma. Despite these advancements, the clinical results remain suboptimal, highlighting the need for further enhancement of therapeutic options. Current research is focused on addressing these gaps by exploring novel strategies to bolster both innate and adaptive immune responses against cancer, thereby improving the efficacy of immunotherapy for lymphomas.
This research topic aims to explore and develop novel strategies to enhance clinical immunotherapy for both Hodgkin and non-Hodgkin lymphomas. The primary objective is to identify and investigate innovative approaches that can improve the effectiveness of current treatments. This includes examining new methods to augment innate and adaptive immune responses, as well as evaluating relevant preclinical and clinical studies that could lead to better therapeutic outcomes for patients with lymphoid neoplasms.
To gather further insights into the field of lymphoma immunotherapy, we welcome articles addressing, but not limited to, the following themes:
- Tumor microenvironment in Hodgkin and non-Hodgkin lymphomas
- Immune defects in Hodgkin and non-Hodgkin lymphomas
- Studies of innate and adaptive immune responses relevant to immunotherapy for lymphoma
- Use of cellular therapies in Hodgkin and non-Hodgkin lymphomas
- Novel approaches to autologous or allogeneic stem cell transplantation
- Novel combinations with immune checkpoint inhibitors
- Novel combinations with monoclonal antibodies and bispecific antibodies
- Use of antibody-drug conjugates in the treatment of Hodgkin and non-Hodgkin lymphomas
- Cytokine-based immunotherapy for lymphoma
- Vaccine-based immunotherapy for lymphoma